Wegovy Weight Loss: STEP Trial Results in Plain Language
Wegovy is the weight management label of semaglutide, and it has something Ozempic does not: a large trial designed to measure weight loss itself. This page explains the STEP 1 result in plain language, what the number does and does not promise, and the dose and time frame behind it. It is education only, not medical advice.
Wegovy is the weight management label of semaglutide
Wegovy and Ozempic contain the same drug, semaglutide, given as a once weekly injection. The labels divide the work between them. Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management in adults with obesity or overweight, and in adolescents aged 12 and older. Wegovy is also approved to reduce cardiovascular risk in adults with cardiovascular disease and obesity or overweight. Because weight management is its approved job, Wegovy was tested in a dedicated weight loss trial program, and its label dosing goes higher than the diabetes label, to a maintenance dose of 2.4 mg once weekly.
That higher dose, and the trial built around it, is why Wegovy carries the headline weight figures for semaglutide. When you read about semaglutide weight loss results, the numbers almost always come from the Wegovy program rather than from diabetes studies, even when an article uses the Ozempic name. Keeping the brands straight is the first step in reading any result honestly.
How much weight can you lose on Wegovy: the STEP 1 result
The central result comes from STEP 1, the largest trial in the Wegovy program. Adults taking semaglutide 2.4 mg, alongside support to eat less and move more, lost an average of 14.9 percent of their body weight at 68 weeks. The trial lasted well over a year, and participants spent most of it at the full maintenance dose after a gradual build up. To make the percentage concrete with simple arithmetic, a person starting at 100 kilograms who matched the average exactly would finish about 14.9 kilograms lighter. A person starting heavier would lose more in absolute terms at the same percentage, and a person starting lighter would lose less.
Three parts of that sentence deserve emphasis. First, it is an average across a large group, not a result any one person was promised. Second, it was achieved at the 2.4 mg maintenance dose, not at the small starting doses used in the first months. Third, it took 68 weeks. Shorter trials and lower doses produce smaller numbers, and quoting 14.9 percent without the dose and the time frame attached is the most common way this result gets misused online.
An average is not a promise
Inside the STEP 1 average sits a wide spread of individual experiences. Some participants lost considerably more than the average, some lost close to it, and some lost little weight at all despite staying in the trial. That spread is normal for every weight treatment ever studied, and it is why honest pages report averages as averages. If your own loss after some months is below the trial average, that does not by itself mean the medicine is failing, just as an above average loss does not guarantee the result will hold forever.
The trial context also matters. Participants received structured support with eating and activity, attended regular follow ups, and had their doses managed by a study team. Real world treatment can look different, with longer gaps between appointments and doses held back because of side effects or supply issues. A fair expectation for your own treatment is the direction and rough scale of the trial result, applied patiently over a similar length of time, rather than the exact figure.
The dose behind the result
Wegovy is not started at 2.4 mg. The published schedule builds up in steps of 0.25 mg, 0.5 mg, 1 mg and 1.7 mg, with each step lasting at least four weeks, before reaching the 2.4 mg maintenance dose. The label maintenance dose is 2.4 mg once weekly, or 1.7 mg if 2.4 mg is not tolerated. The slow build exists because the gastrointestinal side effects, such as nausea and vomiting, are strongest when the dose jumps, and a gradual schedule gives the body time to adjust. The full schedule is set out on the Wegovy dosage chart page on this site.
The practical consequence is that the clock on trial style results starts later than people expect. The first months are mostly titration, at doses well below the one the STEP 1 result was measured on. Judging Wegovy by the first six or eight weeks is like judging a marathon runner by the warm up. Prescribers usually review progress over many months at the maintenance dose before deciding whether treatment is working well enough to continue.
How the loss builds over time
Spread evenly as simple arithmetic, the STEP 1 total works out to a little under 1 percent of starting body weight per month across the roughly 16 months of the trial. That is a rough average only, a way of picturing the scale of the result, and real progress is not even. Loss is usually slower during the titration months, steadier once the maintenance dose is reached, and punctuated by plateaus that can last for weeks even when nothing has changed in your habits. Plateaus are a normal feature of weight loss physiology, not a sign you have done something wrong.
Appetite effects often arrive before the scale moves much. Many people notice smaller portions satisfying them, less interest in snacking, and quieter background thoughts about food in the early weeks, while measurable weight change builds behind those changes. Eating enough protein during this period matters, because when total intake falls, some of the weight lost can be muscle. The eating guidance on this site, including the page on what to eat on Wegovy, covers protein targets and portion habits in detail.
Keeping the result, and staying safe
The STEP program also studied what happens after treatment stops, and the answer shapes how prescribers frame Wegovy from the start. In the STEP 1 extension, people regained about two thirds of the lost weight within a year of stopping semaglutide. Weight management with this class is therefore usually planned as long term treatment, in the same way blood pressure treatment is, rather than as a short course with a permanent effect. Stopping is sometimes the right choice for personal or medical reasons, but it should be a planned conversation, not a surprise.
On safety, Wegovy carries the semaglutide class boxed warning about thyroid C cell tumors, and it should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Common effects are gastrointestinal and are most likely during dose increases, and the label advises stopping semaglutide at least 2 months before a planned pregnancy. Your own doctor or pharmacist can put these points in the context of your history, which no general page can do.
Frequently asked questions
How much weight can you lose on Wegovy?
In STEP 1, the main Wegovy trial, adults on the 2.4 mg maintenance dose lost an average of 14.9 percent of their body weight at 68 weeks, with diet and activity support. It is a group average over more than a year of treatment. Individual results spread widely around it, with some people losing much more and some losing very little.
How long does Wegovy take to produce its full result?
The headline trial result was measured at 68 weeks, and the dose itself takes months to build up, since each step lasts at least four weeks before the 2.4 mg maintenance dose is reached. Appetite changes often come early, but judging the full effect fairly means thinking in terms of a year or more at maintenance, not the first few weeks.
What dose of Wegovy is used for weight loss?
The label maintenance dose is 2.4 mg once weekly, reached through steps of 0.25 mg, 0.5 mg, 1 mg and 1.7 mg, each lasting at least four weeks. If 2.4 mg is not tolerated, the label maintenance alternative is 1.7 mg once weekly. Your prescriber decides the pace and can hold a dose for longer.
Do you have to stay on Wegovy to keep the weight off?
For most people, stopping leads to regain. In the STEP 1 extension, participants regained about two thirds of the lost weight within a year of stopping semaglutide, as appetite returned. That is why treatment is usually planned as long term from the start, and why stopping should be discussed with your prescriber rather than done abruptly.
What if I lose very little on Wegovy?
A minority of people lose little on any given weight treatment, and it does not always show up early, since the first months are spent at lower titration doses. If progress is still minimal after a fair period at the maintenance dose, that is a prescriber conversation about continuing, switching within the class, or other options, not a personal failure.